JP2022008474A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022008474A5 JP2022008474A5 JP2021153626A JP2021153626A JP2022008474A5 JP 2022008474 A5 JP2022008474 A5 JP 2022008474A5 JP 2021153626 A JP2021153626 A JP 2021153626A JP 2021153626 A JP2021153626 A JP 2021153626A JP 2022008474 A5 JP2022008474 A5 JP 2022008474A5
- Authority
- JP
- Japan
- Prior art keywords
- variant
- protoxin
- pain
- isolated
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 101000844259 Thrixopelma pruriens Beta/omega-theraphotoxin-Tp2a Proteins 0.000 claims 37
- 101000654386 Homo sapiens Sodium channel protein type 9 subunit alpha Proteins 0.000 claims 16
- 102000048004 human SCN9A Human genes 0.000 claims 15
- 208000002193 Pain Diseases 0.000 claims 13
- 229920001184 polypeptide Polymers 0.000 claims 11
- 102000004196 processed proteins & peptides Human genes 0.000 claims 11
- 108090000765 processed proteins & peptides Proteins 0.000 claims 11
- 238000002866 fluorescence resonance energy transfer Methods 0.000 claims 10
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 210000004027 cell Anatomy 0.000 claims 8
- 230000000694 effects Effects 0.000 claims 7
- 210000004899 c-terminal region Anatomy 0.000 claims 6
- 238000012217 deletion Methods 0.000 claims 6
- 230000037430 deletion Effects 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 238000003556 assay Methods 0.000 claims 5
- 230000028161 membrane depolarization Effects 0.000 claims 5
- 108020001507 fusion proteins Proteins 0.000 claims 4
- 102000037865 fusion proteins Human genes 0.000 claims 4
- 208000004296 neuralgia Diseases 0.000 claims 4
- 206010044652 trigeminal neuralgia Diseases 0.000 claims 4
- 208000008035 Back Pain Diseases 0.000 claims 2
- 206010058019 Cancer Pain Diseases 0.000 claims 2
- 208000000094 Chronic Pain Diseases 0.000 claims 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 2
- 206010015150 Erythema Diseases 0.000 claims 2
- 208000001640 Fibromyalgia Diseases 0.000 claims 2
- 102000008100 Human Serum Albumin Human genes 0.000 claims 2
- 108091006905 Human Serum Albumin Proteins 0.000 claims 2
- 208000032984 Intraoperative Complications Diseases 0.000 claims 2
- 208000001294 Nociceptive Pain Diseases 0.000 claims 2
- 206010033645 Pancreatitis Diseases 0.000 claims 2
- 208000004983 Phantom Limb Diseases 0.000 claims 2
- 206010056238 Phantom pain Diseases 0.000 claims 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- 208000004550 Postoperative Pain Diseases 0.000 claims 2
- 206010037660 Pyrexia Diseases 0.000 claims 2
- 208000002847 Surgical Wound Diseases 0.000 claims 2
- 208000005298 acute pain Diseases 0.000 claims 2
- 230000006378 damage Effects 0.000 claims 2
- 231100000321 erythema Toxicity 0.000 claims 2
- 239000000835 fiber Substances 0.000 claims 2
- 230000004968 inflammatory condition Effects 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 208000014674 injury Diseases 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 230000001314 paroxysmal effect Effects 0.000 claims 2
- 210000000578 peripheral nerve Anatomy 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 210000000278 spinal cord Anatomy 0.000 claims 2
- 208000020431 spinal cord injury Diseases 0.000 claims 2
- 230000008733 trauma Effects 0.000 claims 2
- 208000009935 visceral pain Diseases 0.000 claims 2
- 102000009027 Albumins Human genes 0.000 claims 1
- 108010088751 Albumins Proteins 0.000 claims 1
- 102100031367 Sodium channel protein type 9 subunit alpha Human genes 0.000 claims 1
- 150000001408 amides Chemical group 0.000 claims 1
- DNSISZSEWVHGLH-UHFFFAOYSA-N butanamide Chemical group CCCC(N)=O DNSISZSEWVHGLH-UHFFFAOYSA-N 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 150000001732 carboxylic acid derivatives Chemical group 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- MGJXBDMLVWIYOQ-UHFFFAOYSA-N methylazanide Chemical group [NH-]C MGJXBDMLVWIYOQ-UHFFFAOYSA-N 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562142069P | 2015-04-02 | 2015-04-02 | |
| US62/142,069 | 2015-04-02 | ||
| JP2017551164A JP6985151B2 (ja) | 2015-04-02 | 2016-03-31 | プロトキシン−ｉｉ変異体及びその使用方法 |
| PCT/US2016/025247 WO2016161100A1 (en) | 2015-04-02 | 2016-03-31 | Protoxin-ii variants and methods of use |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017551164A Division JP6985151B2 (ja) | 2015-04-02 | 2016-03-31 | プロトキシン−ｉｉ変異体及びその使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022008474A JP2022008474A (ja) | 2022-01-13 |
| JP2022008474A5 true JP2022008474A5 (enExample) | 2022-01-20 |
Family
ID=57006450
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017551164A Expired - Fee Related JP6985151B2 (ja) | 2015-04-02 | 2016-03-31 | プロトキシン−ｉｉ変異体及びその使用方法 |
| JP2021153626A Withdrawn JP2022008474A (ja) | 2015-04-02 | 2021-09-21 | プロトキシン－ｉｉ変異体及びその使用方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017551164A Expired - Fee Related JP6985151B2 (ja) | 2015-04-02 | 2016-03-31 | プロトキシン−ｉｉ変異体及びその使用方法 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US10463714B2 (enExample) |
| EP (2) | EP3960757A1 (enExample) |
| JP (2) | JP6985151B2 (enExample) |
| KR (1) | KR20170134542A (enExample) |
| CN (1) | CN107921089A (enExample) |
| AR (1) | AR104173A1 (enExample) |
| AU (2) | AU2016242905B2 (enExample) |
| BR (1) | BR112017020896A2 (enExample) |
| CA (1) | CA2981336A1 (enExample) |
| ES (1) | ES2888799T3 (enExample) |
| IL (2) | IL254599B (enExample) |
| MA (1) | MA41864A (enExample) |
| MX (1) | MX2017012654A (enExample) |
| TW (1) | TW201708249A (enExample) |
| UY (1) | UY36602A (enExample) |
| WO (1) | WO2016161100A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10414808B2 (en) | 2012-05-18 | 2019-09-17 | Janssen Biotech, Inc. | Huwentoxin-IV variants and methods of use |
| ES2841173T3 (es) | 2013-10-03 | 2021-07-07 | Janssen Biotech Inc | Variantes de Protoxina-II y métodos de uso |
| MA41642A (fr) | 2015-03-03 | 2018-01-09 | Janssen Biotech Inc | Variants de protoxine ii et méthodes d'utilisation |
| MX2017012654A (es) | 2015-04-02 | 2018-01-09 | Janssen Biotech Inc | Variantes de protoxina-ii y metodos de uso. |
| TWI724392B (zh) | 2018-04-06 | 2021-04-11 | 美商美國禮來大藥廠 | 生長分化因子15促效劑化合物及其使用方法 |
| CN109369784B (zh) * | 2018-11-14 | 2019-08-30 | 青海芬陀利华生物科技有限公司 | PaTx-1毒素及其应用 |
| WO2021252448A1 (en) * | 2020-06-10 | 2021-12-16 | Memorial Sloan Kettering Cancer Center | Imaging compounds selective for nav1.7 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4309989A (en) | 1976-02-09 | 1982-01-12 | The Curators Of The University Of Missouri | Topical application of medication by ultrasound with coupling agent |
| US4767402A (en) | 1986-07-08 | 1988-08-30 | Massachusetts Institute Of Technology | Ultrasound enhancement of transdermal drug delivery |
| ATE484572T1 (de) | 1997-04-16 | 2010-10-15 | Unigene Lab Inc | Direkte expression von peptiden ins kulturmedium |
| IL120943A (en) | 1997-05-29 | 2004-03-28 | Univ Ben Gurion | A system for administering drugs through the skin |
| US6670127B2 (en) | 1997-09-16 | 2003-12-30 | Egea Biosciences, Inc. | Method for assembly of a polynucleotide encoding a target polypeptide |
| DE69841578D1 (de) | 1997-09-16 | 2010-05-06 | Centocor Inc | Methoden zur kompletten chemischen Synthese und Zusammensetzung von Genen und Genomen |
| US20030148273A1 (en) * | 2000-08-26 | 2003-08-07 | Shoulian Dong | Target enrichment and amplification |
| EP1348466A3 (en) | 2002-02-01 | 2003-10-29 | Inspire Pharmaceuticals, Inc. | Method for treating pain with adenosine-tetraphosphates |
| US7659082B2 (en) | 2002-02-19 | 2010-02-09 | Xenon Pharmaceuticals Inc. | Methods for identifying analgesic agents |
| US7833979B2 (en) | 2005-04-22 | 2010-11-16 | Amgen Inc. | Toxin peptide therapeutic agents |
| CA2626584A1 (en) | 2005-11-04 | 2007-05-18 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of nav1.8 gene |
| WO2007109324A2 (en) | 2006-03-21 | 2007-09-27 | Xenon Pharmaceuticals, Inc. | Potent and selective nav 1.7 sodium channel blockers |
| BRPI0716228A2 (pt) | 2006-09-08 | 2013-10-15 | Mayo Foundation | Polipeptídeos aquaréticos e natriuréticos carecendo de atividade vasodilatadora |
| WO2008033564A1 (en) | 2006-09-15 | 2008-03-20 | Hydra Biosciences Inc. | Compounds for modulating trpv3 function |
| WO2008088422A2 (en) | 2006-10-25 | 2008-07-24 | Amgen Inc. | Toxin peptide therapeutic agents |
| AU2009288088B2 (en) | 2008-09-03 | 2014-12-04 | Nono Inc. | Agents and methods for treatment of pain |
| WO2010104115A1 (ja) | 2009-03-10 | 2010-09-16 | 独立行政法人産業技術総合研究所 | 膜タンパク質を特異的に認識するポリペプチドの調製方法 |
| JP5555891B2 (ja) | 2009-09-15 | 2014-07-23 | アロモネ プリクリニカル リミテッド | クモ毒から単離した新規ペプチド及びその使用 |
| JP5795341B2 (ja) | 2010-03-08 | 2015-10-14 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | 参照ブロック配列によるｆｕｌｌＣＯＬＤ−ＰＣＲ濃縮 |
| US9279003B2 (en) * | 2010-07-07 | 2016-03-08 | Purdue Pharma L.P. | Analogs of sodium channel peptide toxin |
| CN101979411A (zh) | 2010-10-21 | 2011-02-23 | 湖南师范大学 | 虎纹捕鸟蛛蛋白酶抑制剂 |
| EA201370161A1 (ru) | 2011-01-18 | 2013-12-30 | Амген Инк. | НОКАУТНЫЕ ПО Na1.7 МЫШИ И ИХ ПРИМЕНЕНИЕ |
| WO2012151560A2 (en) | 2011-05-04 | 2012-11-08 | Biocept, Inc. | Methods for detecting nucleic acid sequence variants |
| US10414808B2 (en) | 2012-05-18 | 2019-09-17 | Janssen Biotech, Inc. | Huwentoxin-IV variants and methods of use |
| EP2852397B1 (en) | 2012-05-18 | 2022-02-16 | Janssen Biotech, Inc. | Huwentoxin-iv variants and methods of use |
| US9102751B2 (en) | 2012-05-18 | 2015-08-11 | Janssen Biotech, Inc. | Huwentoxin-IV variants and methods of use |
| WO2014016673A1 (en) | 2012-07-27 | 2014-01-30 | Purdue Pharma L.P. | Sodium channel blocking peptides and the use thereof |
| US10344060B2 (en) | 2013-03-12 | 2019-07-09 | Amgen Inc. | Potent and selective inhibitors of Nav1.7 |
| CN104065367B (zh) | 2013-03-20 | 2017-11-07 | 江苏多维科技有限公司 | 一种低功耗磁电阻开关传感器 |
| ES2841173T3 (es) * | 2013-10-03 | 2021-07-07 | Janssen Biotech Inc | Variantes de Protoxina-II y métodos de uso |
| MA41642A (fr) * | 2015-03-03 | 2018-01-09 | Janssen Biotech Inc | Variants de protoxine ii et méthodes d'utilisation |
| MX2017012654A (es) | 2015-04-02 | 2018-01-09 | Janssen Biotech Inc | Variantes de protoxina-ii y metodos de uso. |
-
2016
- 2016-03-31 MX MX2017012654A patent/MX2017012654A/es unknown
- 2016-03-31 CN CN201680020883.XA patent/CN107921089A/zh active Pending
- 2016-03-31 KR KR1020177031290A patent/KR20170134542A/ko not_active Withdrawn
- 2016-03-31 ES ES16774187T patent/ES2888799T3/es active Active
- 2016-03-31 AU AU2016242905A patent/AU2016242905B2/en not_active Ceased
- 2016-03-31 EP EP21189427.4A patent/EP3960757A1/en not_active Withdrawn
- 2016-03-31 TW TW105110361A patent/TW201708249A/zh unknown
- 2016-03-31 CA CA2981336A patent/CA2981336A1/en not_active Abandoned
- 2016-03-31 BR BR112017020896A patent/BR112017020896A2/pt not_active Application Discontinuation
- 2016-03-31 WO PCT/US2016/025247 patent/WO2016161100A1/en not_active Ceased
- 2016-03-31 JP JP2017551164A patent/JP6985151B2/ja not_active Expired - Fee Related
- 2016-03-31 MA MA041864A patent/MA41864A/fr unknown
- 2016-03-31 EP EP16774187.5A patent/EP3277304B1/en active Active
- 2016-04-01 AR ARP160100893A patent/AR104173A1/es not_active Application Discontinuation
- 2016-04-04 US US15/090,328 patent/US10463714B2/en not_active Expired - Fee Related
- 2016-04-04 UY UY0001036602A patent/UY36602A/es unknown
-
2017
- 2017-09-19 IL IL254599A patent/IL254599B/en active IP Right Grant
-
2019
- 2019-11-04 US US16/673,750 patent/US11083776B2/en not_active Expired - Fee Related
-
2021
- 2021-04-21 IL IL282508A patent/IL282508A/en unknown
- 2021-08-09 US US17/397,586 patent/US20220054590A1/en not_active Abandoned
- 2021-09-21 JP JP2021153626A patent/JP2022008474A/ja not_active Withdrawn
- 2021-11-12 AU AU2021266345A patent/AU2021266345A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022008474A5 (enExample) | ||
| CN102143970A (zh) | α-促黑素细胞激素的肽类似物 | |
| JP5750373B2 (ja) | 慢性炎症性応答の調節および自己免疫疾患の処置のためのｉｌ−４由来ペプチド | |
| JP2011510019A5 (enExample) | ||
| JPH08510715A (ja) | フィブロネクチン及び関連コラーゲン−結合性タンパク質のペプチド阻害剤 | |
| JPH05508860A (ja) | 細胞接着制御環状化合物 | |
| JP2010504336A5 (enExample) | ||
| JPH07508025A (ja) | インスリン様増殖因子（ｉｇｆ−１）類似体 | |
| JPWO2021119516A5 (enExample) | ||
| NZ337955A (en) | Modified TNF-alpha and their use as vaccines | |
| CN101511873A (zh) | 用于抑制神经递质分泌的融合多肽和递送该融合多肽的方法 | |
| CA2261562A1 (en) | Fusion polypeptides comprising an ige-binding domain and a hsa component, and their diagnostic and therapeutic uses | |
| CN105612173A (zh) | 用于治疗心力衰竭的环状apelin衍生物 | |
| US20100099609A1 (en) | eAPP AND DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE | |
| IL106271A (en) | Ligand to TNF 75P receptor and its preparation | |
| CN108350032A (zh) | 调节γC-细胞因子活性 | |
| JPH02188600A (ja) | Ｂｓｆ↓２アンタゴニスト | |
| JP4303958B2 (ja) | 環状ペプチドとその調製方法並びに血管形成阻害薬又は促進薬としての用途 | |
| EP0648783B1 (en) | TNF inhibitors | |
| US8470964B2 (en) | Peptides derived from NCAM (FGLs) | |
| CN116813701B (zh) | 靶向肌肉型乙酰胆碱受体的肽分子及其制备方法、用途 | |
| JPWO2021229076A5 (enExample) | ||
| Liu et al. | New peptides structurally related to VEGF-A165 exon-7 and-8 encoded domains antagonize its binding to NRP-1 and VEGF-R1 | |
| EP3333184A1 (en) | Compositions and methods for inhibiting cd279 interactions | |
| JP2025508820A (ja) | Ｃｒｆ２受容体アゴニスト及び治療法におけるそれらの使用 |